>
Swedish Orphan Biovitrum AB (publ) logo

SOBI - Swedish Orphan Biovitrum AB (publ) Share Price

SEK134.5 -5.2  -3.7%

Last Trade - 05/05/21

Sector
Healthcare
Size
Large Cap
Market Cap £3.50bn
Enterprise Value £4.61bn
Revenue £1.21bn
Position in Universe 165th / 1836
Bullish
Bearish
Unlock SOBI Revenue
Momentum
Relative Strength (%)
1m -3.27%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -42.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
3,228 5,204 6,511 9,139 14,248 15,261 14,702 15,990 +36.4%
+1,125 +43.0 +110.3 +33.0 -17.0 -28.1 +17.4
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2021, SwedishOrphan Biovitrum AB (publ) revenues decreased 21% toSEK3.66B. Net income decreased 41% to SEK696M. Revenuesreflect Haemophilia - Elocta segment decrease of 37% toSEK857M, Immunology - Synagis segment decrease of 27% toSEK879M. Net income also reflects Research and developmentcosts increase of 31% to SEK471M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for SOBI
Graphical History

Revenue

SOBI Revenue Unlock SOBI Revenue

Net Income

SOBI Net Income Unlock SOBI Revenue

Normalised EPS

SOBI Normalised EPS Unlock SOBI Revenue

PE Ratio Range

SOBI PE Ratio Range Unlock SOBI Revenue

Dividend Yield Range

SOBI Dividend Yield Range Unlock SOBI Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
SOBI EPS Forecasts Unlock SOBI Revenue
Profile Summary

Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.

Directors
Last Annual December 31st, 2020
Last Interim March 31st, 2021
Public Since September 15, 2006
No. of Shareholders: 33,816
No. of Employees: 1,508
Sector Healthcare
Industry Pharmaceuticals
Index FTSE Euromid ,
Exchange OMX Nordic Exchange Stockholm
Shares in Issue 294,899,478
Free Float (0.0%)
Eligible for
ISAs
SIPPs
SOBI Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for SOBI
Upcoming Events for SOBI
Wednesday 21st July, 2021
Q2 2021 Swedish Orphan Biovitrum AB (publ) Earnings Release
Thursday 28th October, 2021
Q3 2021 Swedish Orphan Biovitrum AB (publ) Earnings Release
Frequently Asked Questions for Swedish Orphan Biovitrum AB (publ)
What is the Swedish Orphan Biovitrum AB (publ) share price?

As of 05/05/21, shares in Swedish Orphan Biovitrum AB (publ) are trading at SEK134.5, giving the company a market capitalisation of £3.50bn. This share price information is delayed by 15 minutes.

How has the Swedish Orphan Biovitrum AB (publ) share price performed this year?

Shares in Swedish Orphan Biovitrum AB (publ) are currently trading at SEK134.5 and the price has moved by -25.24% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Swedish Orphan Biovitrum AB (publ) price has moved by -42.03% over the past year.

What are the analyst and broker recommendations for Swedish Orphan Biovitrum AB (publ)?

Of the analysts with advisory recommendations for Swedish Orphan Biovitrum AB (publ), there are there are currently 2 "buy" , 5 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Swedish Orphan Biovitrum AB (publ) is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Swedish Orphan Biovitrum AB (publ) next release its financial results?

Swedish Orphan Biovitrum AB (publ) is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-03-31
What is the Swedish Orphan Biovitrum AB (publ) dividend yield?

Swedish Orphan Biovitrum AB (publ) does not currently pay a dividend.

Does Swedish Orphan Biovitrum AB (publ) pay a dividend?

Swedish Orphan Biovitrum AB (publ) does not currently pay a dividend.

When does Swedish Orphan Biovitrum AB (publ) next pay dividends?

Swedish Orphan Biovitrum AB (publ) does not currently pay a dividend.

How do I buy Swedish Orphan Biovitrum AB (publ) shares?

To buy shares in Swedish Orphan Biovitrum AB (publ) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Swedish Orphan Biovitrum AB (publ)?

Shares in Swedish Orphan Biovitrum AB (publ) are currently trading at SEK134.5, giving the company a market capitalisation of £3.50bn.

Where are Swedish Orphan Biovitrum AB (publ) shares listed? Where are Swedish Orphan Biovitrum AB (publ) shares listed?

Here are the trading details for Swedish Orphan Biovitrum AB (publ):

Country of listing: Sweden
Exchange: STO
Ticker Symbol: SOBI
What kind of share is Swedish Orphan Biovitrum AB (publ)?

Based on an overall assessment of its quality, value and momentum, Swedish Orphan Biovitrum AB (publ) is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Swedish Orphan Biovitrum AB (publ) share price forecast 2021?

Shares in Swedish Orphan Biovitrum AB (publ) are currently priced at SEK134.5. At that level they are trading at 36.15% discount to the analyst consensus target price of 0.00.

Analysts covering Swedish Orphan Biovitrum AB (publ) currently have a consensus Earnings Per Share (EPS) forecast of 7.101 for the next financial year.

How can I tell whether the Swedish Orphan Biovitrum AB (publ) share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Swedish Orphan Biovitrum AB (publ). Over the past six months, the relative strength of its shares against the market has been -26.69%. At the current price of SEK134.5, shares in Swedish Orphan Biovitrum AB (publ) are trading at -16.88% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Swedish Orphan Biovitrum AB (publ) PE Ratio?

The Swedish Orphan Biovitrum AB (publ) PE ratio based on its reported earnings over the past 12 months is 17.03. The shares are currently trading at SEK134.5.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Swedish Orphan Biovitrum AB (publ)?

Swedish Orphan Biovitrum AB (publ)'s management team is headed by:

Matthew Gantz - IND
Annette Clancy - IND
Hakan Bjorklund - CHM
Milan Zdravkovic - VRD
Armin Reininger - CSO
Guido Oelkers - PRE
Henrik Stenqvist - CFO
David Allsop - IND
Torbjorn Hallberg - GCN
Norbert Oppitz - OTH
Pia Axelson - DRC
Anne De Jonge Schuermans - CTO
Sofiane Fahmy - OTH
Paula Treutiger - DIR
Kristin Sandberg - DRC
Who are the major shareholders of Swedish Orphan Biovitrum AB (publ)?

Here are the top five shareholders of Swedish Orphan Biovitrum AB (publ) based on the size of their shareholding:

Investor AB Private Equity
Percentage owned: 35.41% (107.6m shares)
Fjärde AP-Fonden Pension Fund
Percentage owned: 5.04% (15.3m shares)
Swedbank Robur Fonder AB Investment Advisor/Hedge Fund
Percentage owned: 4.88% (14.8m shares)
EdgePoint Investment Group Inc. Investment Advisor
Percentage owned: 4.8% (14.6m shares)
Handelsbanken Asset Management Investment Advisor/Hedge Fund
Percentage owned: 3.05% (9.28m shares)
Similar to SOBI
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.